Jacques‐Olivier Bay

Outcomes and treatment patterns of patients with primary mediastinal B‐cell lymphoma after CAR‐T cell therapy failure: A DESCAR‐T analysis

Jean Galtier, Pierre Sesques, Vivien Dupont, Emmanuel Bachy et autres

fr (code pays fourni par la source)

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Guillaume Manson, Cécile Pizot, Emmanuel Bachy, Catherine Thieblemont et autres

Abstract Introduction The optimal use of bridging therapy (BT) prior to anti-CD19 CAR T-cell therapy in large B-cell lymphoma (LBCL) remains uncertain. Response to BT has been associated with improved progression-free survival (PFS) (Rodie C et al., Blood Adv 2023), suggesting that …

fr, us (code pays fourni par la source)

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurélien Belot, Emmanuel Bachy, Hervé Ghesquières et autres

Abstract IntroductionThe treatment landscape of early relapsed/refractory (R/R) large B-cell lymphoma (LBCL) has been transformed by anti-CD19 CAR T-cells. In ZUMA-7, transplant-intended early R/R LBCL patients treated with axicabtagene ciloleucel (axi-cel) had longer event-free survival (EFS) than those receiving standard salvage chemoimmunotherapy …

fr (code pays fourni par la source)

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Jean Galtier, Pierre Sesques, Vivien Dupont, Emmanuel Bachy et autres

Abstract Background : Primary mediastinal B-cell lymphoma (PMBL) is a rare subtype of large B-cell lymphoma that usually responds well to frontline immunochemotherapy but has historically had a poor prognosis in the relapsed/refractory (R/R) setting. Although anti-CD19 CAR-T cell therapy has shown …

fr (code pays fourni par la source)

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros et autres

Abstract Background: Relapse after CAR T-cell therapy in large B-cell lymphoma (LBCL) is associated with poor prognosis, lacking a clear salvage standard and supported by limited evidence. Patients receiving second-line (2L) CAR T-cells typically have high-risk features, such as chemo-refractory disease or …

fr (code pays fourni par la source)

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Caroline Houillier, Elena Robin-Marieton, Cécile Pizot, Roch Houot et autres

Abstract Introduction Lymphomas with central nervous system (CNS) involvement were excluded from major clinical trials on anti-CD19 CAR T-cells due to concerns about potential unacceptable neurotoxicity. Recently, several studies have shown promising results of this therapy in primary or secondary CNS lymphomas, …

fr (code pays fourni par la source)

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Gabriel Brisou, Emmanuel Bachy, Elodie Gat, Guillaume Cartron et autres

Abstract Background Axicabtagene ciloleucel (axi-cel) and Lisocabtagene maraleucel (liso-cel), two anti-CD19 CAR T-cells, have been approved as 2nd line (2L) treatment in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) for patients progressing within 12 months of first-line chemo-immunotherapy, based on the ZUMA-7 and …

fr (code pays fourni par la source)

Éclectisme et diversité, le numéro d’un monde idéal

Jacques‐Olivier Bay, Stéphane Vignot, Philippe Pourquier, Nathalie Mazure

fr (code pays fourni par la source)

Anti‐ CD19 CAR T‐cell therapy for patients with Richter transformation: A LYSA study from the DESCAR ‐T registry

Hedi Bensaber, Emmanuelle Ferrant, Rémy Duléry, David Beauvais et autres

All data generated or analysed during this study are subject to controlled access by the Lymphoma Academic Research Organization (LYSARC) owing to privacy and legal requirements and proprietary reasons. LYSARC data can be re-used for the purposes of conducting research in the …

fr (code pays fourni par la source)

446 | IMPACT OF RESPONSE TO HOLDING/BRIDGING THERAPY IN SECOND‐LINE DLBCL PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL: A LYSA STUDY FROM THE FRENCH DESCAR‐T REGISTRY

Antoine Capes, Alessandro Cuozzo, Elodie Gat, Andr�e Marquet et autres

to receive concurrent cancer-directed therapies.Data on tumor responses in mHLH patients were collected when available.Results: Fifteen patients with mHLH secondary to lymphoma were treated with ELA026.Tumor responses were assessed in 6 patients with R/R lymphoma: 2 with angioimmunoblastic T-cell lymphoma, 2 with …

fr (code pays fourni par la source)

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire ( SFGM ‐ TC )

Yves Chalandon, Raynier Devillier, Ariane Boumendil, Stéphanie Nguyen et autres

There are very limited data regarding the outcomes of elderly patients with acute lymphoblastic leukemia (ALL) who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 316 ALL patients aged ≥ 60 years who underwent alloHSCT between 2010 to 2022 were …

ch, fr, be, lb, Algérie (code pays fourni par la source)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry

Jean Galtier, Charles Mesguich, Pierre Sesques, Vivien Dupont et autres

Primary mediastinal B-cell lymphoma (PMBL) is often cured with dose-dense anthracycline-based regimens but the prognosis at relapse or progression remains poor. While anti-CD19 CAR-T cell therapy has dramatically improved outcomes in relapsed or refractory large B-cell lymphoma, far less is known about …

fr (code pays fourni par la source)